Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

CNTB

+ Watchlist+ Portfolio

Connect Biopharma Holdings Limited

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.58
52-Week Range
$0.55 – $3.82
Market Cap
$42.90M
P/E (TTM)
—
EPS (TTM)
-1.35
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.48
PEG Ratio
—
Return on Equity
-201.53%
Return on Assets
-90.73%
Gross Margin
100.00%
Operating Margin
-1879.91%
Profit Margin
0.00%
Current Ratio
1.49
Debt/Equity
0.04
Total Debt
$496.00K
Free Cash Flow
$-29.68M
Revenue Growth
4500.00%
Earnings Growth
—
Enterprise Value
$23.90M

Market Snapshot

About

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and immunologic diseases. Headquartered in San Diego, California, with research facilities in Suzhou, China, the company leverages its expertise in T cell biology and immune modulation. Connect Biopharma's lead product candidate, CBP-201, is an anti-IL-4Rα antibody being developed for atopic dermatitis and other allergic inflammatory conditions. The company has additional programs targeting various immune-mediated diseases using its proprietary technology platforms. Connect Biopharma utilizes a dual-geography strategy, conducting clinical development in both China and the United States to accelerate timelines and access diverse patient populations.